NASDAQ:BDRX Biodexa Pharmaceuticals Q4 2025 Earnings Report $4.58 +0.17 (+3.73%) As of 12:30 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Biodexa Pharmaceuticals EPS ResultsActual EPS$3.53Consensus EPS -$0.01Beat/MissBeat by +$3.53One Year Ago EPSN/ABiodexa Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABiodexa Pharmaceuticals Announcement DetailsQuarterQ4 2025Date3/27/2026TimeBefore Market OpensConference Call DateFriday, March 27, 2026Conference Call Time8:00AM ETConference Call ResourcesAnnual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(20-F) Biodexa Pharmaceuticals Earnings HeadlinesBiodexa Pharmaceuticals PLC - Depositary receipt (BDRX) price target decreased by 80.56% to 35.70April 9, 2026 | msn.comBiodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial SuppliesApril 2, 2026 | globenewswire.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.May 7 at 1:00 AM | American Alternative (Ad)Tanner Pharma Group and Biodexa Launch Global Early Access Program for FAP PatientsMarch 31, 2026 | finance.yahoo.comBDRX: Initiating coverage of Biodexa Pharmaceuticals; a deep value oncology platform built around two high-conviction areasMarch 30, 2026 | msn.comPreliminary Results for the Year Ended 31 December 2025March 27, 2026 | globenewswire.comSee More Biodexa Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biodexa Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biodexa Pharmaceuticals and other key companies, straight to your email. Email Address About Biodexa PharmaceuticalsBiodexa Pharmaceuticals (NASDAQ:BDRX) Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.View Biodexa Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amprius Technologies Ups the Voltage on Forward OutlookWhy Lam Research Still Looks Like a Buy After a 300% RallySuper Micro Surges Over 20% as Margins Soar, Sales Fall ShortNuts and Bolts AI Play Gains Momentum: Astera Labs Targets RaisedAnheuser-Busch Stock Jumps as Volume Growth Signals TurnaroundLight Speed Returns: Corning Cashes In on NVIDIA GrowthBoarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage Upcoming Earnings AngloGold Ashanti (5/8/2026)Brookfield Asset Management (5/8/2026)Enbridge (5/8/2026)Toyota Motor (5/8/2026)Ubiquiti (5/8/2026)Constellation Energy (5/11/2026)Barrick Mining (5/11/2026)Petroleo Brasileiro S.A.- Petrobras (5/11/2026)Simon Property Group (5/11/2026)SEA (5/12/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
